2021
Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes: Results from the DREAM Study.
Ding Q, Qin L, Wojeck B, Inzucchi SE, Ibrahim A, Bravata DM, Strohl KP, Yaggi HK, Zinchuk AV. Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes: Results from the DREAM Study. Annals Of The American Thoracic Society 2021, 18: 2067-2078. PMID: 34185617, PMCID: PMC8641817, DOI: 10.1513/annalsats.202012-1556oc.Peer-Reviewed Original ResearchConceptsApnea-hypopnea indexObstructive sleep apneaPolysomnographic phenotypeIncident T2DMRisk of T2DMPredictive valueSleep apneaBlood glucoseRisk factorsCardiovascular diseaseMild obstructive sleep apneaIncident type 2 diabetesMultivariable-adjusted regression modelsCox proportional hazards regressionNew physician diagnosisT2DM risk predictionIncident cardiovascular diseaseIncident type 2Body mass indexProportional hazards regressionT2DM risk factorsBehavioral risk factorsType 2 diabetesMale veteran populationRisk regression models
2020
Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial
Yaggi H, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi S, Wanner C, Zwiener I, Wojeck B, Neeland I, Johansen O. Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. European Heart Journal 2020, 41: ehaa946.2883. DOI: 10.1093/ehjci/ehaa946.2883.Peer-Reviewed Original ResearchEMPA-REG OUTCOMECardiovascular diseaseIncidence rateMajor adverse CV eventsPlacebo-controlled outcome trialsAdverse CV eventsGlomerular filtration rateSystolic blood pressureCox regression modelStandard of careType 2 diabetesCV deathCV eventsCV outcomesMultivariable adjustmentInhibitor empagliflozinOutcome trialsBlood pressureHeart failureWaist circumferenceMortality outcomesSodium glucoseFiltration rateMetabolic disturbancesPatients